Beta-Turn Peptidomimetic Cyclization via Solution-Phase Nucleophilic Substitution
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for synthesizing β-turn cyclic peptidomimetic compounds face challenges in large-scale production, particularly with the formation of dimeric side products and lack of cost-effective solutions for in vivo and clinical studies.
Innovation Solution
A new synthetic methodology involving cyclization in the solution phase, using protected linear peptidomimetic compounds and intramolecular aromatic nucleophilic substitution, followed by deprotection of amino acid side chains, to produce β-turn peptidomimetic cyclic compounds efficiently, reducing dimeric side product formation and improving scalability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If traditional synthesis methods are used for β-turn cyclic peptidomimetic compounds, then the compounds can be synthesized, but dimeric side products are formed and production costs increase
Solution Approach 1:
The patent changes the physical state parameter of the reaction system from solid-phase to solution-phase cyclization. This parameter change fundamentally alters the reaction environment, allowing better control over intermolecular interactions that lead to dimerization while maintaining intramolecular cyclization efficiency. The solution-phase environment enables optimized solvent selection and concentration control to suppress side reactions.
2Productivity
If traditional synthesis methods are used, then compounds can be produced, but scalability to gram and kilogram quantities is difficult
Solution Approach 1:
The patent utilizes phase transition by moving the cyclization reaction from solid-phase to solution-phase. This transition enables the reaction to be conducted in homogeneous liquid media, which is much more amenable to scale-up operations. Solution-phase reactions allow for better heat transfer, mass transfer, and mixing at larger scales, making gram and kilogram production feasible while maintaining reaction efficiency.
3Quantity of substance
If existing synthetic methodologies are applied, then β-turn cyclic peptidomimetic compounds can be synthesized, but production is not cost-effective for in vivo and clinical studies
Solution Approach 1:
The patent employs preliminary protection of amino acid side chains with appropriate protecting groups before cyclization. This preliminary action prevents unwanted side reactions during the cyclization step and subsequent handling, thereby improving overall yield and reducing material waste. The protecting groups are strategically selected to be stable during cyclization but removable under mild conditions, preserving the integrity of the target compound throughout the synthesis process.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables cost-effective and efficient production of β-turn cyclic peptidomimetic compounds on a large scale, minimizing dimeric side product formation and enhancing the feasibility of in vivo and clinical studies.
Implementation Method 1
cyclizing in a solution phase the protected linear peptidomimetic compound of formula (III) to form a protected β-turn peptidomimetic cyclic compound of formula (IV) by an intramolecular aromatic nucleophilic substitution
Data Source
Figure 1
Figure 2
AI summary
The present invention relates to methods of preparing ?-turn cyclic peptidomimetic compounds and intermediates thereof. Particularly, the present invention relates to a process for the synthesis of ?-turn cyclic peptidomimetic compounds of formula (I) where R1, R2, R3, R4, R5, R6, R7, L2, X, Y and n are as defined in the specification. The present invention provides a more efficient route for preparing ?-turn cyclic peptidomimetic compounds and intermediates thereof.